From Meatballs to $1 Billion: How Mama's Creations Is Conquering the Deli Aisle
Why It Matters
Mama's Creations’ aggressive consolidation could redefine the prepared‑food market, offering investors a high‑growth, margin‑rich play while giving retailers a single source for diverse deli offerings.
Key Takeaways
- •Mama's Creations pivots to one‑stop deli solution in market.
- •Revenue surged 50% to $47.3 million in Q3 2025.
- •New leadership team drives margins above 30 percent for the company.
- •Growth split: 50% organic, 50% acquisitions, targeting $1 billion.
- •Expanding footprint to 100,000 sq ft across all 50 states.
Summary
Mama's Creations Inc., a formerly niche meatball maker, announced a strategic shift to become a one‑stop shop for prepared deli foods, aiming to dominate the $40 billion prepared‑food aisle. The company, now listed under ticker MA, reports presence in more than 12,000 grocery, club and mass‑market locations nationwide and a stock surge of over 70 % in 2025.
In the third quarter, revenue jumped 50 % to $47.3 million, while gross margins climbed from 11.9 % to above 30 %. The growth plan is evenly split between organic expansion—adding roughly seven SKUs per store and increasing velocity—and inorganic deals, including the recent acquisition of a Cisco‑division and Creative Salads, which added 67,000 sq ft of production capacity.
CEO Adam Michaels emphasized the “one‑truck, one‑partner” model, noting that retailers currently juggle 25 separate suppliers and EDI systems. He highlighted the newly assembled executive team—former heads from Bors Head, Tate, Walmart, Gordon Foods and a publicly‑traded CFO—as a catalyst for operational excellence and rapid scale.
If the company sustains its 20 % annual organic growth and 50 % acquisition‑driven expansion, it projects a $1 billion valuation within the next few years. Success would reshape the deli landscape, pressure traditional meat‑and‑cheese producers, and give retailers a streamlined supply chain amid rising food‑away‑from‑home inflation.
Comments
Want to join the conversation?
Loading comments...